linjc16/ctgov huggingface dataset:
Experience of Rehabilitation Amongst Individuals With Paraplegia

Study Overview
=================
Brief Summary
-----------------
This study is a qualitative study exploring the facilitators to physical and vocational rehabilitation and also explores the barriers in empowering individuals with paraplegia

Detailed Description
-----------------
Spinal cord injury is one of the most distressing medical conditions being encountered by today's health care system. In India incidence of Spinal cord injury accounts for 20 per million per years population with 20,000 cases added every year. Rehabilitation services are of utmost importance in empowering these individuals. So there is a need for more qualitative studies through which needs in rehabilitation services can be upgraded. The aim of the study is to explore the experience of physical and vocational rehabilitation amongst the individuals with paraplegia in India

Official Title
-----------------
Experience of Physical and Vocational Rehabilitation Amongst Individuals With Paraplegia

Conditions
-----------------
Spinal Cord Injuries

Intervention / Treatment
-----------------
* Other: Semi-structured interviews


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Traumatic & Non-Traumatic paraplegics Both male & female above 18 yrs of age Time since injury of minimum 6 months Community dwelling paraplegics Exclusion Criteria: Communication problems Psychiatric problems or co morbidities like head injury

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Individuals with Paraplegia<br>After screening the participants according to the inclusion/exclusion criteria, informed consent will be obtained from all the selected participants. Their demographic details will be obtained and asked for their comfortable time for the interview. Data will be collected by in-depth face to face, semi- structured interviews. Audio/video recording of the interview will be taken & it will be written in English and will be transcribed verbatim also manual notes will be prepared for their analysis after the interview is conducted | Other: Semi-structured interviews<br>* Semi-structured interviews with individuals with paraplegia<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Semi-structured interview | Semi-structured interview with audio/video recording | 30minutes-45 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
qualitative research, paraplegia, rehabilitation
Evaluation of Mechanisms Responsible for Coma in Patients Affected by Fulminant, Acute and Chronic Hepatic Failure

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to understand mechanisms associated with the development of coma during hepatic failure. As of today, those mechanisms are not understood and it is difficult to intervene and prevent coma development which is often associated with mortality. Understanding the mechanism involved, may allow us to prevent coma and develop new therapies to treat this disease.

Official Title
-----------------
Evaluation of Mechanisms Responsible for Coma in Patients Affected by Fulminant, Acute and Chronic Hepatic Failure

Conditions
-----------------
Acute and Chronic Hepatic Failure With Developing Coma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients (male or female), 18 years or older hospitalized or seen at UTMB clinics for chronic or acute hepatic failure will be included in the study. Exclusion Criteria: Patients (male or female), 18 years or older hospitalized or seen at UTMB clinics that do not have a diagnosis of chronic or acute hepatic failure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| acute or chronic hepatic failure<br>All patients presenting at University of Texas Medical Branch (UTMB) with acute and chronic hepatic failure and who are developing coma | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The relationship that exist between a liver undergoing chronic or acute degeneration and hepatic coma. |  | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acute hepatic failure, chronic hepatic failure, coma
Phase I/II Study of Curdlan Sulfate

Study Overview
=================
Brief Summary
-----------------
To assess the safety and tolerance of curdlan sulfate, as well as its anti-HIV activity, in HIV-infected patients with CD4 T-lymphocytes less than 500 cells/mm3, using first single doses and then, after FDA review, daily doses for 7 days.

Detailed Description
-----------------
In Phase I of the study, escalating single doses of intravenous curdlan sulfate are tested. In Phase II, curdlan sulfate is administered daily for 7 days. (NOTE: Phase I is completed.)

Official Title
-----------------
Phase I/II Study of Curdlan Sulfate

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Curdlan sulfate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients must have: HIV seropositivity. No current AIDS-defining opportunistic infection, lymphoma, Kaposi's sarcoma, or other malignancy. CD4 count < 500 cells/mm3. No critical illness that would shorten life expectancy to < 16 weeks. Exclusion Criteria Concurrent Medication: Excluded: Antiretroviral or other experimental therapies. Anticoagulants. Steroids. Cytotoxic or immunosuppressive agents. Concurrent Treatment: Excluded: Radiotherapy. Patients with the following prior condition are excluded: History of heparin sensitivity. Prior Medication: Excluded within 1 month prior to study entry: Antiretroviral or other experimental therapies. Anticoagulants. Steroids. Cytotoxic or immunosuppressive agents. Prior Treatment: Excluded: Radiotherapy within 1 month prior to study entry. Active IV drug abuse.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Curdlan sulfate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acquired Immunodeficiency Syndrome, AIDS-Related Complex, curdlan sulfate
Triple Therapy With Tegoprazan in H. Pylori Positive Patients_PILOT

Study Overview
=================
Brief Summary
-----------------
This study aims to compare safety and efficacy in an exploratory manner between a Tegoprazan triple therapy and a RAPAE01 triple therapy in H. pylori positive patients.

Detailed Description
-----------------
A Randomized, Double-Blind, Active-controlled, Multicenter, Pilot Study to Investigate the Safety and Efficacy of a Tegoprazan triple therapy and a RAPAE01 triple therapy in H. pylori positive patients.

Official Title
-----------------
A Randomized, Double-Blind, Active-controlled, Multicenter, Pilot Study to Investigate the Safety and Efficacy of a Triple Therapy With Tegoprazan, Amoxicillin and Clarithromycin in H. Pylori Positive Patients

Conditions
-----------------
Helicobacter Pylori Infection

Intervention / Treatment
-----------------
* Drug: Tegoprazan
* Drug: RAPAE01


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: H. pylori positive at screening Subjects who have upper gastrointestinal disease Exclusion Criteria: Having received prior therapy for eradication of H. pylori Prior use of P-CAB, proton pump inhibitors (PPIs), H2 receptor blockers within 14 days Prior use of H. pylori eradication effective antibiotics, bismuth within 28 days

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Tegoprazan 50 mg<br>Tegoprazan 50 mg Triple Therapy | Drug: Tegoprazan<br>* Tegoprazan 50 mg or 100 mg/Clarithromycin/Amoxicillin BID peroral<br>|
| Experimental: Tegoprazan 100 mg<br>Tegoprazan 100 mg Triple Therapy | Drug: Tegoprazan<br>* Tegoprazan 50 mg or 100 mg/Clarithromycin/Amoxicillin BID peroral<br>|
| Active Comparator: RAPAE01<br>RAPAE01 Triple Therapy | Drug: RAPAE01<br>* RAPAE01/Clarithromycin/Amoxicillin BID peroral<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| H. pylori eradication rate | Assess H. pylori eradication rate by UBT | Day 49 |
Evaluation of Patients With Unusual Diagnostic or Treatment Considerations

Study Overview
=================
Brief Summary
-----------------
This study offers evaluation and treatment of patients with unusual diagnostic or treatment considerations. It is not designed to test new treatments; rather, patients will receive current standard of care treatments. The purposes of the study are: 1) to allow NIDCR staff an opportunity to maintain and improve their clinical skills; and 2) to evaluate referred patients for research potential. (Participants in this protocol will not be required to join a research study; the decision will be voluntary.) Patients in need of dental/oral diagnosis and therapy of interest to NIDCR staff dentists may be eligible for this protocol. Participants will have a comprehensive dental examination and may receive part or all of their treatment at the NIDCR clinic. Diagnostic procedures, materials and treatments used in this study are limited to those widely accepted in dentistry and are non-experimental in nature.

Detailed Description
-----------------
The proposed pilot project will allow the staff of the Dental Clinic Oral Medicine Fellowship Program to accept patients, for diagnosis and conventional therapy, which do not otherwise meet the criteria for any of the current NIDCR research protocols. This clinical examination and therapy by Dental Clinic practitioners will provide an excellent forum for the observation of oral conditions and phenomena that may generate scientific inquiries and provide valuable educational experiences consistent with the goals of the Oral Medicine Program.

Official Title
-----------------
General Dental Diagnostic and Therapeutic Study: A Pilot Program for Evaluating the Research Potential of Referred Subjects

Conditions
-----------------
Healthy, Tooth Disease

Intervention / Treatment
-----------------
* Procedure: current standard of care treatments


Participation Criteria
=================
Eligibility Criteria
-----------------
Patients in need of dental/oral diagnosis and therapy which are of interest to one or more of the staff dentists.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: current standard of care treatments|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
General Dental, Diagnostic, Therapeutic
Iron Substitution After Upper Gastro-Intestinal Bleeding

Study Overview
=================
Brief Summary
-----------------
The trial is a double-blind randomized trial designed to examine whether compliant iron therapy (intravenous or oral) for 3 months after discharge increases hemoglobin levels more and faster than no treatment - in patients with acute bleeding from upper gastrointestinal tract. The trial will include 126 patients at Aarhus University Hospital. In addition to efficacy assessment quality of life assessment and health economic calculations between the treatments will be compared.

Official Title
-----------------
Comparison of the Efficacy of Compliant Oral Iron Treatment (FerroDuretter ®) for 3 Months After Discharge Versus Single-dose of Intravenous Iron (Ferinject ®) Before Discharge in Patients With Acute Bleeding From Upper Gastrointestinal Tract. A Double Blinded Randomized Trial

Conditions
-----------------
Gastrointestinal Hemorrhage, Anemia

Intervention / Treatment
-----------------
* Drug: ferricarboxymaltose
* Drug: Ferrosulfate
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acute upper gastrointestinal bleeding Anemia Exclusion Criteria: Liver disease Terminal cancer Kidney disease variceal bleeding Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Intravenous iron<br> | Drug: ferricarboxymaltose<br>* Single dose of maximum 1000 mg ferricarboxymaltose intravenous<br>* Other names: Ferinject;|
| Active Comparator: Oral iron<br> | Drug: Ferrosulfate<br>* 200mg daily for 12 weeks<br>* Other names: FerroDuretter;|
| Placebo Comparator: Isotonic Sodium and placebo tablets<br> | Drug: Placebo<br>* 100 mg isotonic sodium and 2 placebo tablets daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| haemoglobin |  | 13 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life Health economics |  | 13 weeks, 6 and 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Iron treatment, Upper gastrointestinal bleeding
Impact of Ibis on Patients With Advanced COPD

Study Overview
=================
Brief Summary
-----------------
The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients with COPD.

Official Title
-----------------
Impact of Ibis, a Digital Health Solution for Patient Activation and Early Intervention, on Acute Care Utilization by Patients With Advanced COPD

Conditions
-----------------
COPD

Intervention / Treatment
-----------------
* Behavioral: Digital Therapeutics


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gold Stage II with a CAT Score above 19 Gold Stage III/IV with a CAT Score above 14 Exclusion Criteria: Cognitive or physical impediments that inhibits patients from interacting with our digital therapeutics platform.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Digital Therapeutics<br>Patients assigned to the digital therapeutics arm will receive Ibis and all the associate services. | Behavioral: Digital Therapeutics<br> <br> |
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction in Acute Care Utilization |  | 6 months and then again at 1 year |
Effect of Open-placebo Intervention on Cycling Performance

Study Overview
=================
Brief Summary
-----------------
This study evaluates the effect of an open-label placebo intervention on cycling time-trial performance.

Detailed Description
-----------------
This study investigated the effect of open-placebo on cycling time-trial (TT) performance. Twenty-eight trained female cyclists completed a 1-km cycling TT following a control session or an open-placebo intervention. The intervention consisted of an individual presentation, provided by a medic, in which the concept of open-placebo was explained to the participant, before she ingested two red and white capsules containing flour; 15 min later, they performed the TT. In the control session, the participant sat quietly for 20 min.

Official Title
-----------------
The Effect of an Open-placebo Intervention on Cycling Time-trial Performance

Conditions
-----------------
Exercise Performance

Intervention / Treatment
-----------------
* Behavioral: Open-placebo
* Behavioral: Control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Females aged between 18 and 45 years old; A minimum of one-year training experience in cycling. Exclusion Criteria: Smokers Chronic disease Prior or current use of steroids Use of creatine in the last 6 months Use of beta-alanine in the last 6 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Open-placebo<br>The open-placebo intervention session | Behavioral: Open-placebo<br>* Application of the open-placebo intervention<br>|
| Placebo Comparator: Control<br>The control session | Behavioral: Control<br>* Application of the control session<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Exercise performance | Change in 1 km cycling time-trial performance | 20-min following open-placebo intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood lactate | Change in blood lactate concentration | Immediately post-exercise |
Impact of Exercise Training on Endothelial Function in CAD

Study Overview
=================
Brief Summary
-----------------
Bradykinin has been identified to contribute to the release of nitric oxide (NO), prostacyclin, and EDHF through activation of specific bradykinin 2 (B2) receptors, which is finally promoting a vasodilatory respone. Regular physical exercise training results in an improvement of endothelial function in patients with CAD. These positive effects were partially attributed to an increased expression of endothelial NO synthase (eNOS) and cyclooxygenase (COX) as a result of the training intervention. Aim of this trial is therefore to determine, whether the training-induced correction of endothelial dysfunction is also bradykinin-dependent.

Detailed Description
-----------------
A total of 20 patients with stable coronary artery disease are prospectively randomized to 4 weeks of exercise training or sedentary lifestyle. Endothelial function of the radial artery is determined by a high-resolution A-mode ultrasound.

Official Title
-----------------
Impact of Exercise Training on Bradykinin-Mediated Endothelial Function in Patients With Coronary Artery Disease

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Behavioral: Exercise Training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: stable CAD male gender Exclusion Criteria: insulin-dependent diabetes mellitus significant valvular heart disease smoking exercise-induced myocardial ischemia conditions prohibiting exercise training

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Educational/Counseling/Training
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Exercise Training|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Endothelial function |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
exercise training, endothelial function